Literature DB >> 19830561

Trends in gastroesophageal reflux disease as measured by the National Ambulatory Medical Care Survey.

Frank K Friedenberg1, Alexandra Hanlon, Vishwas Vanar, Dawit Nehemia, Jyothi Mekapati, Deborah B Nelson, Joel E Richter.   

Abstract

BACKGROUND: The prevalence of reflux disease is increasing. Health-care utilization including physician visits for this disorder is lacking. Our purpose was to analyze the trend in physician visits for GERD from the period 1995-2006 using the National Ambulatory Medical Care Survey. We also sought to determine health-care utilization for GERD indirectly by assessing prescription trends for proton-pump inhibitors and H2 receptor blockers during the period.
METHODS: The National Ambulatory Medical Care Survey is a survey of approximately 3,000 office-based physicians that uses a three-stage probability sampling procedure to allow extrapolation to the US population. All visits between 1995 and 2006 for symptoms and/or diagnoses compatible with GERD were combined into a single categorical variable. Weighted data was utilized for descriptive and inferential statistical analysis.
RESULTS: After weighting, there were N = 321,513 adult ambulatory care encounters for all diagnoses. Visits for reflux increased throughout the examined period. Using logistic regression, visits for reflux were associated with female gender, age over 40, and calcium channel blocker use. Proton-pump inhibitor use increased substantially during the study period while H2 blocker use declined. Family practitioners and internists saw the majority of reflux patients.
CONCLUSIONS: The frequency of ambulatory visits in the United States for gastroesophageal reflux disease increased significantly between 1995 and 2006. The use of PPI therapy is increasing even more substantially. Older age, female gender, and use of calcium channel blockers were associated with a higher frequency of GERD visits. Health-care utilization for this disorder is increasing perhaps due to our ever-increasing epidemic of obesity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19830561     DOI: 10.1007/s10620-009-1004-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

2.  Heartburn and globus in apparently healthy people.

Authors:  W G Thompson; K W Heaton
Journal:  Can Med Assoc J       Date:  1982-01-01       Impact factor: 8.262

3.  Risk factors associated with symptoms of gastroesophageal reflux.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Am J Med       Date:  1999-06       Impact factor: 4.965

4.  Association between body mass and adenocarcinoma of the esophagus and gastric cardia.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Ann Intern Med       Date:  1999-06-01       Impact factor: 25.391

5.  Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients.

Authors:  E Kuster; E Ros; V Toledo-Pimentel; A Pujol; J M Bordas; L Grande; C Pera
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

6.  Manometric oesophageal function, acid perfusion test and symptomatology in a 55-year-old general population.

Authors:  G Kjellén; L Tibbling
Journal:  Clin Physiol       Date:  1981-08

7.  Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease.

Authors:  S J Spechler; S K Jain; D A Tendler; R A Parker
Journal:  Aliment Pharmacol Ther       Date:  2002-10       Impact factor: 8.171

8.  Importance of reflux symptoms in functional dyspepsia.

Authors:  P K Small; M A Loudon; B Waldron; D Smith; F C Campbell
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

9.  Gastro-oesophageal reflux associated with nifedipine.

Authors:  L R Jenkinson; T L Norris; A Watson
Journal:  Aliment Pharmacol Ther       Date:  1988-08       Impact factor: 8.171

10.  Analysis of NAMCS data for multiple sclerosis, 1998-2004.

Authors:  Jagannadha R Avasarala; Cormac A O'Donovan; Steve E Roach; Fabian Camacho; Steven R Feldman
Journal:  BMC Med       Date:  2007-04-05       Impact factor: 8.775

View more
  27 in total

1.  Oral nitrate reductase activity and erosive gastro-esophageal reflux disease: a nitrate hypothesis for GERD pathogenesis.

Authors:  Siavosh Nasseri-Moghaddam; Habibeh Nokhbeh-Zaeem; Parastoo Saniee; Shahrzad Pedramnia; Masoud Sotoudeh; Reza Malekzadeh
Journal:  Dig Dis Sci       Date:  2011-09-01       Impact factor: 3.199

2.  GERD in Minority Populations.

Authors:  Frank K Friedenberg
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-06

3.  Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.

Authors:  Erik J Snider; Griselda Compres; Daniel E Freedberg; Hossein Khiabanian; Yael R Nobel; Stephania Stump; Anne-Catrin Uhlemann; Charles J Lightdale; Julian A Abrams
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-29       Impact factor: 4.254

4.  Many patients continue using proton pump inhibitors after negative results from tests for reflux disease.

Authors:  Andrew J Gawron; Jami Rothe; Angela J Fought; Anita Fareeduddin; Erin Toto; Lubomyr Boris; Peter J Kahrilas; John E Pandolfino
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-22       Impact factor: 11.382

5.  Low Prevalence of Suspected Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease Without Alarm Symptoms.

Authors:  Emery C Lin; Jennifer Holub; David Lieberman; Chin Hur
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

Review 6.  Endoluminal Therapy for Gastroesophageal Reflux Disease: In Between the Pill and the Knife?

Authors:  Tony S Brar; Peter V Draganov; Dennis Yang
Journal:  Dig Dis Sci       Date:  2016-10-28       Impact factor: 3.199

7.  Elective antireflux surgery in the US: an analysis of national trends in utilization and inpatient outcomes from 2005 to 2010.

Authors:  Luke M Funk; Aliyah Kanji; W Scott Melvin; Kyle A Perry
Journal:  Surg Endosc       Date:  2014-01-01       Impact factor: 4.584

8.  Symptom index P-value and symptom sensitivity index P-value to determine symptom association between apnea and reflux in premature infants at term.

Authors:  D R Glen; P Murakami; J S Nunez
Journal:  Dis Esophagus       Date:  2012-11-16       Impact factor: 3.429

9.  Prevalence and risk factors for gastroesophageal reflux disease in an impoverished minority population.

Authors:  Frank K Friedenberg; Jitha Rai; Vishwas Vanar; Charles Bongiorno; Deborah B Nelson; Mayur Parepally; Arashdeep Poonia; Amol Sharma; Shaun Gohel; Joel E Richter
Journal:  Obes Res Clin Pract       Date:  2010-10       Impact factor: 2.288

10.  Associations between medication use and functional gastrointestinal disorders: a population-based study.

Authors:  R S Choung; G R Locke; C D Schleck; A R Zinsmeister; N J Talley
Journal:  Neurogastroenterol Motil       Date:  2013-01-29       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.